Community/Retail

The FDA has accepted Sandoz's biologics license application for its proposed pegfilgrastim biosimilar.

The updated 2015 Beers Criteria includes 3 new medications and 2 new medication classes, as well as 2 new completely new sections.

Obesity is one of America's greatest health challenges, affecting more than one-third of US adults.

In addition to facing the risk of fatal overdose, kidney disease, and pneumonia, heroin users also have a greater likelihood of acquiring HIV.

CVS Health has announced that Repatha from Amgen will be added as the only PCSK9 inhibitor on the CVS/caremark commercial formularies.

CVS has unveiled savings for ExtraCare Rewards members during a three-day Black Friday sales event at all 7,900 CVS/pharmacy locations.

Rite Aid stores nationwide are celebrating the busiest shopping weekend of the year by giving customers the opportunity to earn Plenti points on a variety of holiday essentials.

AstraZeneca has entered into an agreement with Perrigo for the divestment of US rights to Entocort, a gastroenterology medicine for patients with mild to moderate Crohn's disease.

A pharmacist in Indiana is looking to leverage pharmacists' professional judgment in determining a patient's need for pseudoephedrine products that can be used to make meth.

Long-term care pharmacies' current prescription drug reimbursement model may not be sustainable, a new analysis suggests.

Are there any benefits in applying snail extract to your face?

The boards of directors of Pfizer and Allergan have unanimously approved a definitive merger agreement under which Pfizer will combine with Allergan.

Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, discusses why she thinks her pharmacy was named best Retail Advantage by Cardinal Health.

Liz Tiefenthaler, president of Pharm Fresh Media, talks about how telling your pharmacy story can improve your pharmacy's brand and nurture patient loyalty.

Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can maintain business continuity during a natural disaster or other emergencies.

Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some ways independent pharmacists could encourage local prescribers to adopt e-prescribing of controlled substances.

Liz Tiefenthaler, president of Pharm Fresh Media, provides some examples of how marketing techniques or outreach efforts differ based on patient demographics.

Women with type 2 diabetes have greater difficulty with exercise than those without the condition.

Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, gives some examples of sustainable business models that can expand the role of the pharmacist.

Mylan has successfully completed the acquisition of certain women's healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care Limited.

Pharmacists may be better able to help patients stop abusing prescription drugs if they can pinpoint what adverse effects they are experiencing and why.

The world of Internet marketing is a burgeoning business.

Mylan is launching generic versions of Glucotrol, Axert, and Viramune extended-release tablets.

Get Smart About Antibiotics Week leads into NACDS Foundation Dinner, which makes possible new research to battle antibiotic resistance.

A leader of a pharmacist-managed gout clinic has some insight that can help pharmacists improve the management of their patients' gout.

This weekly video program highlights the latest in pharmacy news, product news, and more.

CVS Health, Express Scripts, and the National Community Pharmacists Association were among the stakeholders to recently testify on the state of competition in the pharmacy benefit manager and pharmacy marketplace.

Carlos Aquino, founder and president of PharmaDiversion LLC, reviews some of the DEA's requirements for handling controlled substances.

A group of San Diego, California, pharmacies and their owners have paid $750,000 to the federal government to resolve drug diversion claims.